The new olanzapine depot formulation for intramuscular administration facilitates treatment adherence in schizophrenia. However, it has been associated with an uncommon but serious adverse effect referred to as post-injection syndrome, characterized by a series of symptoms consistent with olanzapine overdose. As a result, its use is limited and patients must be monitored for several hours after the injection. We report the first known case of post-injection syndrome at our hospital and its management.

Maria Magdalena Parera Pascual

Alejandra Mandilego Garcia

Júlia Rodriguez Martin

Beatriz Calderón Hernanz

European journal of clinical pharmacy

European Journal of Clinical Pharmacy®, is a peer reviewed biomedical journal that publish papers related to clinical pharmacy, clinical pharmacology, pharmacoepidemiology, pharmacoeconomics, pharmacotherapy and clinical management in the following sections, not necessary included in every issue.

The European Journal of Clinical Pharmacy® is a peer-reviewed biomedical journal that publishes papers related to clinical pharmacy, clinical pharmacology, pharmacoepidemiology, pharmacoeconomics, pharmacotherapy, and clinical management. The journal covers various sections, which may not necessarily be included in every issue.

《European Journal of Clinical Pharmacy》是一本经过同行评审的生物医学期刊，发表与临床药学、临床药理学、药物流行病学、药物经济学、药物治疗和临床管理相关的论文。期刊的内容涵盖多个领域，具体内容可能在每期中有所不同。

Post-injection syndrome after olanzapine long-acting injection: A case report

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info